RxCelerate’s U.K. headquarters on the Babraham Research Campus in Cambridge, U.K. (left) and U.S. headquarters at One Broadway, Cambridge, Mass. (right). (Credit: RxCelerate via PR Newswire)
RxCelerate, an outsourced drug discovery and development firm based in Cambridge, U.K., has opened its first U.S. location in Cambridge, Mass. and hired Laura Hamilton as executive VP to lead the new operation.
Hamilton previously served as the director of business development at the Massachusetts Biotechnology Council (MassBio), a not-for-profit organization founded in 1985 that represents and provides services and support for members in the Massachusetts life sciences cluster.
RxCelerate offers integrated discovery and development services ranging from medicinal chemistry, antibody discovery, preclinical safety and efficacy, through to clinical proof of concept.
In a press statement, David Grainger, executive chairman at RxCelerate, differentiated the company from typical Contract Research Organizations. “RxCelerate is different,” he said. “We are architects of drug discovery and development, rather than builders. Our clients need provide nothing more than the target they are interested in, and RxCelerate will deliver a pharma-grade product candidate and progress it into the clinic.”
Founded in 2012 in the U.K., RxCelerate reports that its clients range from start-ups through to three of the top 15 global pharmaceutical companies, and that it already serves clients in the U.S.
The U.K.’s Department for International Trade, a government department responsible for striking trade agreements between the U.K. and non-EU states, served as advisers in development of the firm’s international trade strategy during the past two years leading up to the opening of the Massachusetts office.
The company specializes in in vivo pharmacology, offering proprietary models of a range of human diseases, as well as complex cell-based assays. Its chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates with in vitro testing capability to deliver pharma-grade drug product candidates “at a fraction of the cost of traditional approaches,” according to RxCelerate.
Contact information for the new U.S. headquarters: [email protected]; (857) 409-6028; One Broadway, Cambridge, Mass. 02142.
(Source: RxCelerate)
